Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
Dermatology, Claudius Regaud Institute, Comprehensive Cancer Center, 20-24, rue du Pont Saint-Pierre, 31052 Toulouse, France. Electronic address: sibaud.vincent@claudiusregaud.fr.
Vincent
V
Sibaud
Medical Oncology, Claudius Regaud Institute, Comprehensive Cancer Center, Toulouse, France.
Christine
C
Chevreau
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004387:Dupuytren Contracture / Q000139:chemically induced*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
BRAF inhibitor; Dupuytren; Vemurafenib